Carteolol Hydrochloride | CAS#51781-21-6 | β-Adrenergic blocker

Carteolol Hydrochloride
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317376

CAS#: 51781-21-6

Description: Carteolol hydrochloride is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects.

Chemical Structure

Carteolol Hydrochloride

CAS# 51781-21-6

Instruction

Theoretical Analysis

MedKoo Cat#: 317376
Name: Carteolol Hydrochloride
CAS#: 51781-21-6
Chemical Formula: C16H25ClN2O3
Exact Mass: 0.00
Molecular Weight: 328.830
Elemental Analysis: C, 58.44; H, 7.66; Cl, 10.78; N, 8.52; O, 14.60

Price and Availability

Size	Price	Availability
50mg	USD 300	2 weeks
100mg	USD 550	2 Weeks
250mg	USD 950	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Carteolol Hydrochloride ; Carteolol HCl; Arteoptic; Cartrol; Mikelan; Abbott-43326; Hydrochloride, Carteolol; Monohydrochloride, Carteolol; OPC 1085; OPC-1085; OPC1085;

IUPAC/Chemical Name: 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one;hydrochloride

InChi Key: FYBXRCFPOTXTJF-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H24N2O3.ClH/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13;/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20);1H

SMILES Code: CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 328.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Yao Q, Yu X, Zheng T, Liu H, Yang Y, Yi P. Spectroscopic studies on the
interaction of carteolol hydrochloride and urea-induced bovine serum albumin.
Spectrochim Acta A Mol Biomol Spectrosc. 2013 Sep;113:447-51. doi:
10.1016/j.saa.2013.04.129. Epub 2013 May 16. PubMed PMID: 23747387.

2: Chikama T, Araie M, Nishida T. [Influence on ocular surface and intraocular
pressure of switching from preservative-containing to preservative-free carteolol
hydrochloride ophthalmic solution]. Nippon Ganka Gakkai Zasshi. 2013
May;117(5):419-26. Japanese. PubMed PMID: 23855234.

3: Ishida S, Mochimaru H, Nagai N, Noda K, Ozawa Y. [Effects of carteolol
hydrochloride on experimental choroidal neovascularization]. Nippon Ganka Gakkai
Zasshi. 2011 Apr;115(4):355-61. Japanese. PubMed PMID: 21598603.

4: Kawase K, Yamamoto T, Muramatsu T, Ono J, Nakajima T, Matsuhisa A, Sugiura T,
Migita M, Ishikawa Y. [Long-acting carteolol hydrochloride 2% ophthalmic solution
phase IV study--investigation of the effectiveness, safety and plasma
concentration]. Nippon Ganka Gakkai Zasshi. 2010 Nov;114(11):976-82. Japanese.
PubMed PMID: 21141077.

5: Kaji Y, Kiuchi T, Oshika T. Carteolol hydrochloride suppresses the generation
of reactive oxygen species and rescues cell death after ultraviolet irradiation
of cultured lens epithelial cells. Open Ophthalmol J. 2010 Oct 12;4:60-5. doi:
10.2174/1874364101004010060. PubMed PMID: 21283534; PubMed Central PMCID:
PMC3031156.

6: Nakamoto K, Yasuda N. Effect of carteolol hydrochloride on 24-hour variation
of intraocular pressure in normal-tension glaucoma. Jpn J Ophthalmol. 2010
Mar;54(2):140-3. doi: 10.1007/s10384-009-0780-6. Epub 2010 Apr 18. PubMed PMID:
20401563.

7: Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A. Carteolol hydrochloride
protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea.
2005 Mar;24(2):213-20. PubMed PMID: 15725891.

8: Kawai K, Kuwahara K, Oizumi N, Kitagaki H, Fujisawa S. Effects of carteolol
hydrochloride on the in vitro production of LPS-induced proinflammatory cytokines
by murine macrophage. J Ocul Pharmacol Ther. 2004 Jun;20(3):237-45. PubMed PMID:
15279728.

9: Isawa S, Murasaki M, Miura S, Yoshioka M, Uchiumi M, Kumagai Y, Aoki S,
Hisazumi H, Kudo S. Pharmacokinetic and pharmacodynamic interactions among
haloperidol, carteolol hydrochloride and biperiden hydrochloride. Nihon Shinkei
Seishin Yakurigaku Zasshi. 1999 Jul;19(3):111-8. PubMed PMID: 10495985.

10: Kober G, Veidt J, Mikludy R, Kaltenbach M. [Heart rate behavior and the
ischemic ST-segment under carteolol hydrochloride. Dose-response relationship and
duration of effect]. Arzneimittelforschung. 1983;33(2a):313-7. German. PubMed
PMID: 6682323.

11: El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic
gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan-Feb;13(1):55-9.
PubMed PMID: 16401594.

12: Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL. Efficacy of carteolol
hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular
pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am
J Ophthalmol. 1997 Oct;124(4):498-505. PubMed PMID: 9323940.

13: Kudo S, Umehara K, Abe Y, Furukawa M, Odomi M. Intracerebral penetration of
carteolol hydrochloride in rats. Psychopharmacology (Berl). 1997
Jun;131(4):388-93. PubMed PMID: 9226741.

14: Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular
effects of topical carteolol hydrochloride and timolol maleate in patients with
ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J
Ophthalmol. 1997 Apr;123(4):465-77. PubMed PMID: 9124243.

15: Kikuchi T, Uwahodo Y, Tottori K, Nakai M, Morita S. The attenuating effect of
carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced
catalepsy in rats. Psychopharmacology (Berl). 1997 May;131(2):108-14. PubMed
PMID: 9201797.

16: van Husen H. [1% carteolol hydrochloride eyedrops: long-term experience in
the treatment of chronic open-angle glaucoma]. Klin Monbl Augenheilkd. 1986
Dec;189(6):491-5. German. PubMed PMID: 3550260.

17: Mizuki K, Yamazaki Y. [Effect of carteolol hydrochloride on ocular blood flow
dynamics in normal human eyes]. Nippon Ganka Gakkai Zasshi. 2000
Apr;104(4):226-31. Japanese. PubMed PMID: 10793541.

18: Mirza GE, Karaküçük S, Temel E. Comparison of the effects of 0.5% timolol
maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular
pressure and perimetry findings and evaluation of their ocular and systemic
effects. J Glaucoma. 2000 Feb;9(1):45-50. PubMed PMID: 10708231.

19: Tamagawa M, Numoto T, Tanaka N, Nishino H. Reproduction study of carteolol
hydrochloride in mice. Part 2. Peri -and postnatal toxicity. J Toxicol Sci. 1979
Feb;4(1):59-77. PubMed PMID: 480406.

20: Tanaka N, Shingai F, Tamagawa M, Nakatsu I. Reproduction study of carteolol
hydrochloride in mice. Part I. Fertility and reproductive performance. J Toxicol
Sci. 1979 Feb;4(1):47-58. PubMed PMID: 480405.

Your view history

Carteolol Hydrochloride featured